Zogenix, Inc. has expanded its senior leadership team to support of the planned launch of Zohydro ER (hydrocodone bitartrate) extended-release capsules in March 2014. Bradley S. Galer, M.D., has been appointed executive vice president and chief medical officer. Prior to joining the company, Dr. Galer served as president of the Pain Group at Nuvo Research, where he oversaw the strategy and operations, including commercialization, drug development activities, business development and licensing opportunities. Prior to Nuvo, Dr. Galer served as senior medical officer and group vice president of Scientific Affairs at Endo Pharmaceuticals. He has published more than 200 articles on pain management in peer review journals and textbooks.
Arnold R. Gammaitoni, Pharm.D. has been appointed vice president of Medical and Scientific Affairs. Dr. Gammaitoni previously served as vice president of Scientific Affairs of the Pain Group at Nuvo Research. Prior to Nuvo, Dr. Gammaitoni was global director of Scientific Affairs for Analgesia, Immunology, and Anesthesia at Merck & Co. He also served as senior director of Medical Affairs at Endo Pharmaceuticals. Dr. Gammaitoni has also been a clinical practitioner with a focus on pain management and has authored or co-authored more than 50 articles.
Marsha R. Stanton, Ph.D., RN, has been named executive director of Medical Affairs. Dr. Stanton is nationally known for her work in pain management including clinical practice, public policy and patient education. Prior to joining Zogenix, Dr. Stanton served as executive director of Program Development, External Affairs, Medical Affairs at Horizon Pharma, a specialty pharmaceutical company with three commercialized products focused on arthritis, pain and inflammatory diseases. She held similar positions representing pain products and organizations at Pfizer, King Pharmaceuticals, Alpharma Pharmaceuticals and Purdue.
"We are very pleased to welcome Drs. Galer, Gammaitoni and Stanton to the Zogenix team," said Stephen Farr, Ph.D., president of Zogenix. "They all have a proven track record of successful accomplishments in the development and commercialization of opioid analgesics and other drug products. Under Brad's leadership we are building a strong clinical and medical affairs organization that will be immediately focused on our programs to assure the appropriate use of Zohydro ER, be active participants in the design and execution of the class-wide post marketing requirements for ER opioid analgesics, and advance our development pipeline that includes an abuse deterrent formulation of Zohydro ER."